Birchler Brian's Form 4 filing
Ionis Pharmaceuticals Inc (IONS) · filed Apr 19, 2023
- Accession no.
- 0000874015-23-000132
- Filed
- Apr 19, 2023
- Trade date
- Apr 17-18, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $24.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Birchler BrianCIK 0001970151 | Officer (EVP, Corp and Development Ops) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Common Stock | MOption exerciseAcquired | +1,875 | $0.00 | $0 | 37,200 | Direct | |
| Apr 18, 2023 | Common Stock | SSaleDisposed | −672 | $36.50F3 | −$24,528 | 36,528 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Common Stock | MOption exerciseDisposed | −1,875 | $0.00 | $0 | 27,720 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $36.50953 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Referenced by the price of 1 transaction in Table I.